Doctor Pharmaceuticae - Dpharm / The use of efavirenz (EFV) in the first trimester of pregnancy
remains controversial. In South Africa, the use of EFV-containing antiretroviral
therapy (ART) as part of a Fixed Dose Combination (FDC) during the first
trimester of pregnancy started in April, 2013. Literature to date has reported
conflicting outcomes following the use of EFV-containing ART during the first
trimester of pregnancy. The objectives of the study were to determine the
prevalence of adverse pregnancy outcomes among HIV-positive pregnant women
treated with EFV-containing ART and compare these results with those of pregnant
women treated with NVP-containing ART and HIV-negative pregnant women in
resource-limited settings. In addition, the study also aimed to determine the effect
of the time of initiation of ART on the prevalence of adverse pregnancy outcomes.
| Identifer | oai:union.ndltd.org:netd.ac.za/oai:union.ndltd.org:uwc/oai:etd.uwc.ac.za:11394/6185 |
| Date | January 2017 |
| Creators | Mohammednur, Mohammedmekin Mohammedseid |
| Contributors | Mugabo, Pierre |
| Publisher | University of the Western Cape |
| Source Sets | South African National ETD Portal |
| Language | English |
| Detected Language | English |
| Type | Thesis |
| Rights | University of the Western Cape |
Page generated in 0.0019 seconds